TAM-derived miR-660 competes with inhibitor kappa B kinase β (IKKβ) to bind kelch-like protein 21 (KLHL21), resulting in activation of NF-κB p65 signaling pathways (Figure 3), which lead to breast cancer progression [71]. Here, KLHL21 is linked to breast carcinoma.